|
|
|
|
|
20.05.26 - 09:42
|
BioArctic Interim Report for the period January - March 2026 (PR Newswire)
|
|
|
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded......
|
|
|
20.05.26 - 09:36
|
BioArctic Interim Report for the period January - March 2026 (PR Newswire)
|
|
|
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded......
|
|
|
|
|
|
|
15.05.26 - 08:36
|
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 – March 2027) (Cision)
|
|
|
Stockholm, Sweden, May 15, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding to a 63 percent growth compared to the previous year. This would generate approximately SEK 880 M in royalty to BioArctic during the same period.
Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor...
|
|
|
|
|
13.05.26 - 08:37
|
Invitation to presentation of BioArctic′s first quarter report for January – March 2026 on May 20 at 9:30 a.m. CET (Cision)
|
|
|
Stockholm, Sweden, May 13, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's first quarter report for January – March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET.
In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on May 20, at 9:30 a.m CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the first quarter report, followed by a Q&A session.
If you wish to participate via the webcast, please use the link below, where you will be able to...
|
|
|
08.05.26 - 09:06
|
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. (Cision)
|
|
|
Stockholm, Sweden, May 8, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi® Iqlik™, as a starting dose for the treatment of early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026.
As part of the ongoing review process, the agency requested additional information and has...
|
|
|
08.05.26 - 08:51
|
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. (PR Newswire)
|
|
|
STOCKHOLM, May 8, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly......
|
|
|
29.04.26 - 12:00
|
Sales of Leqembi® totaled 26.2 billion yen in the first quarter 2026 (Cision)
|
|
|
Stockholm, Sweden, April 29, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the first quarter 2026, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 26.2 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 161 million, which is an increase of approximately 68 percent compared to the royalty recorded by BioArctic for the first quarter 2025.
Eisai's results for their fourth quarter and full year FY2025 (April 2025 - March 2026)...
|
|
|
29.04.26 - 12:00
|
Leqembi® annual sales exceed EUR 500 million – second sales milestone achieved (Cision)
|
|
|
Stockholm, Sweden, April 29, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the global sales of Leqembi surpassed EUR 500 million in Eisai's fiscal year 2025 (April 2025 – March 2026), triggering a second sales-related milestone payment of EUR 20 million to BioArctic.
Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for...
|
|
|
|
|
|
|
|
|
|
|
21.04.26 - 20:30
|
Notice of Annual General Meeting 2026 in BioArctic AB (publ) (Cision)
|
|
|
The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday 28 May 2026
For more information on the content of the proposals, please see the complete notice to the Annual General Meeting below. The notice is expected to be published in the Swedish Official Gazette (Post- och Inrikes Tidningar), and in Svenska Dagbladet and on the company's website within the next few days.
NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)
The shareholders in BioArctic AB (publ), corp.reg.no. 556601-2679 (“BioArctic”) are hereby...
|
|
|
21.04.26 - 20:06
|
BioArctic publishes the Annual Report and Sustainability Report for 2025 (Cision)
|
|
|
Stockholm, April 21, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Annual Report for 2025 has been published and is available on the company's website. The company's Sustainability Report and Corporate Governance Report are integrated with the Annual Report.
“In 2025 BioArctic entered a new phase. Behind us, we left an era that, for just over 20 years, shaped the company we are today. 2025 was a fantastic year for BioArctic, with a breakthrough drug against Alzheimer's disease on the global market, a broad and growing pipeline, several license agreements and a...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
